These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27284960)

  • 1. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit.
    Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y
    Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
    Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
    Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients.
    Cheng L; You X; Wang X; Yu M; Jia C
    Drug Des Devel Ther; 2024; 18():3617-3628. PubMed ID: 39156484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
    Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
    J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics in China: The Dynamics of Intravenous Voriconazole in Critically Ill Patients with Pulmonary Disease.
    Chen W; Xie H; Liang F; Meng D; Rui J; Yin X; Zhang T; Xiao X; Cai S; Liu X; Li Y
    Biol Pharm Bull; 2015; 38(7):996-1004. PubMed ID: 26133710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
    Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
    Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
    Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
    Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
    Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
    Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
    Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
    Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole-related visual adverse events.
    Jiang YK; Wang RY; Wang X; Zhao HZ; Zhou LH; Huang LP; Yip CW; Cheng JH; Que CX; Jiang C; Zhu LP
    Mycoses; 2020 Jun; 63(6):579-587. PubMed ID: 32222082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study.
    Taher KW; Almofada R; Alomair S; Albassam AA; Alsultan A
    Paediatr Drugs; 2024 Mar; 26(2):197-203. PubMed ID: 38228969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress.
    Wu SL; Cheng CN; Wang CC; Lin SW; Kuo CH
    Toxicol Appl Pharmacol; 2020 Sep; 403():115157. PubMed ID: 32717240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.
    Amigues I; Cohen N; Chung D; Seo SK; Plescia C; Jakubowski A; Barker J; Papanicolaou GA
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):46-52. PubMed ID: 20053331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.